Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm

Cannon, Paul S.; MacKenzie, Kenneth; Cook, Anne; Leatherbarrow, Brian

doi:10.1111/j.1442-9071.2010.02303.x

Cited by 11 publications

(4 citation statements)

References 16 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings corroborate those published studies. 16,17,18,19,20,21,22,23,24 . The success rate in the present study was 94.73% when injections that did not produce any effect or produced a short-term or minor effect were excluded.…”

Section: Discussionmentioning

confidence: 99%

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

Batisti

Kleinfelder

Galli

et al. 2017

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Hemifacial spasm (HFS) is a craniofacial movement disorder characterized by involuntary contractions of the muscles on one side of the face 1 . The most common site for the contractures is the orbicularis oculi muscle, but the corrugator supercilii, frontalis muscle, orbicularis oris, zygomaticus major and platysma can also be affected 2 . The condition is believed to be mainly due to a peripheral dysfunction of the facial nerve, occasionally associated with nerve compression by a blood vessel or tumor 3,4 . The pathophysiology, however, has yet to be fully elucidated as the condition can occur in the absence of structural alterations 3 . In a recent study, Wilkinson and Kaufmann 5 showed that HFS may be associated with central nervous system changes. Accordingly, one previous study from our group found similar profiles of obsessive and psychiatric symptoms in cases of HFS and blepharospasm, which is recognized as a movement disorders of A total of 550 BTX-A injections were administered to 100 HFS patients. Results: Mean duration of improvement following each injection session was 3.1 months, mean latency to detection of improvement was 7.1 days and mean success rate was 94.7%. Patients were evaluated at an interval of 5.8 months after each application. Adverse effects, which were mostly minor, were observed in 37% of the patients at least once during follow-up. The most frequent was ptosis (35.1%). Conclusion: Treatment of HFS with BTX-A was effective, sustainable and safe and had minimal, well-tolerated side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

Batisti

Kleinfelder

Galli

et al. 2017

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…13,26,27 In another study, Cannon et al found that 90% of patients were satisfied with the effect of their last BTX-A treatment. 28 This satisfaction rate was higher in patients with HFS compared to the patients with BPS. 28 In our study, efficacy seemed to be better in BPS compared to HFS, but it was more stable in HFS after injections, whereas the efficacy trend showed up and down alterations in BPS (Graphic 1).…”

Section: Discussionmentioning

confidence: 87%

“…28 This satisfaction rate was higher in patients with HFS compared to the patients with BPS. 28 In our study, efficacy seemed to be better in BPS compared to HFS, but it was more stable in HFS after injections, whereas the efficacy trend showed up and down alterations in BPS (Graphic 1). This difference between the groups may be due to the small number of patients in the BPS group.…”

Section: Discussionmentioning

confidence: 87%

Efficacy and Safety of Botulinum Toxin Type A (Botox®)' in Blepharospasm and Hemifacial Spasm

Çabalar¹,

Yayla²,

Çulha³

et al. 2013

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

lepharospasm (BPS) and hemifacial spasm (HFS) are the most common movement disorders of the craniofacial area. BPS is a focal dystonia characterized by involuntary and forced closure of eyelids due to spasmodic contractions of the orbital and periorbital muscles. The clinical evidence usually starts with involuntary blinks and strong dystonic contractions that may develop in the orbicularis oculi muscles leading to a functional loss of vision. These spasms may spread to nasal, corrugator and ® was diluted by sterile saline to adjust the dose to 5U/0.1 ml before injection. Pretarsal administration was applied. The average dose of Botox ® required for an optimal response was 30-35 MU for BPS, 25-30 MU for HFS. R Re es su ul lt ts s: : The therapeutic effect started after 3 to 5 days, and initial repetitive efficacy intervals (REI) [2nd REI, BPS (13,9 months) and HFS (5,8 months)] were longer than the last mean REI [7th REI, BPS (5.9 months) and HFS (3.7 months)], and there were statistically significant differences between BPS and HFS groups (p<0.05). The treatment was effective in both BPS and HFS. Adverse effects occurred in 7.29% of the injection series. C Co on nc cl lu us si io on n: : BTX-A is established as an effective and safe agent in the treatment of BPS and HFS. The side effects of BTA-X administration may be reduced with the help of injection material used and the application technique.

show abstract

“…Facial dystonias may effectively be treated with periocular subcutaneous injection of botulinum toxin Vol:. (1234567890) [5,11,12]. These injections produce few local complications, such as ecchymosis, ptosis, or diplopia, and do not generally have systemic effects [13].…”

Section: Introductionmentioning

confidence: 99%

Effects of the periocular botulinum toxin on the ocular surface and anterior chamber: a prospective study in patients with hemifacial spasm and blepharospasm

et al. 2023

View full text Add to dashboard Cite

Purpose To analyze using Pentacam®, the corneal and anterior chamber changes following periocular botulinum toxin injection in patients with facial dystonia. Methods Prospective study that included patients with facial dystonia that were going to receive a periocular botulinum toxin injection for the first time or six months or more after the previous injection. A Pentacam® examination was carried out in all patients before and 4 weeks after the injection. Results Thirty-one eyes were included. Twenty-two had a diagnosis of blepharospasm and nine of hemifacial spasm. Analysis of corneal and anterior chamber parameters revealed a significant decrease in iridocorneal angle after botulinum toxin injection (from 35 ± 10º to 33.8 ± 9.7º, p = 0.022). No other corneal or anterior chamber parameters changed significantly after the injection. Conclusions Periocular botulinum toxin injection causes narrowing of the iridocorneal angle.

show abstract

Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm

Abstract: We have shown that patients with BEB have a shorter duration of effect with BTX and require more frequent BTX treatments than patients with HFS, highlighting that facial dystonias in patients with BEB is more challenging to manage.

Cited by 11 publications

References 16 publications

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated

Efficacy and Safety of Botulinum Toxin Type A (Botox®)' in Blepharospasm and Hemifacial Spasm

Effects of the periocular botulinum toxin on the ocular surface and anterior chamber: a prospective study in patients with hemifacial spasm and blepharospasm

Contact Info

Product

Resources

About